Inactive Instrument

Global Blood Therapeutics, Inc.

Equities

GBT

US37890U1088

Biotechnology & Medical Research

GLOBAL BLOOD THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

June 29, 2022 at 08:04 am EDT

Item 8.01. Other Events.

On June 29, 2022, Global Blood Therapeutics, Inc. issued a press release titled "GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits

Exhibit Number    Description

  99.1              Press Release, dated June 29, 2022
104               Cover Page Interactive Data File (embedded within the Inline
                  XBRL document)

Latest news about Global Blood Therapeutics, Inc.

BioPharma Credit Receives $175 Million From Global Blood Therapeutics Investment	22-10-06	MT
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from S&P Global BMI Index	22-10-06	CI
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from S&P TMI Index	22-10-06	CI
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from S&P Biotechnology Select Industry Index	22-10-06	CI
Global Blood Therapeutics, Inc. Announces Cessation of Ted W. Love as Chief Executive Officer	22-10-05	CI
Global Blood Therapeutics, Inc. Announces Executive Changes	22-10-05	CI
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index	22-10-05	CI
Pfizer Inc. completed the acquisition of Global Blood Therapeutics, Inc. from a group of shareholders.	22-10-04	CI
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Biotechnology Index	22-10-04	CI
Insider Sell: Global Blood Therapeutics	22-09-07	MT
Insider Sell: Global Blood Therapeutics	22-08-19	MT
Biotech stocks pin bounce back hopes on M&A boost	22-08-12	RE
North American Morning Briefing : Caution -2-	22-08-10	DJ
Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Raised to $68.50 From $60 Amid Pfizer Deal	22-08-09	MT
SVB Securities Downgrades Global Blood Therapeutics to Market Perform from Outperform, Sets $68.50 Price Target	22-08-09	MT
Wells Fargo Downgrades Global Blood Therapeutics to Equalweight From Overweight, Adjusts Price Target to $68.50 From $66	22-08-09	MT
Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral From Overweight, Adjusts Price Target to $68.50 From $75	22-08-09	MT
William Blair Downgrades Global Blood Therapeutics to Market Perform From Outperform	22-08-09	MT
Cowen Downgrades Global Blood Therapeutics to Market Perform From Outperform, Adjusts Price Target to $68.50 From $67	22-08-09	MT
North American Morning Briefing : Stocks to -2-	22-08-09	DJ
BioPharma Credit To Receive Loan Prepayment Following Pfizer's Takeover Of Global Blood Therapeutics	22-08-09	MT
Guggenheim Downgrades Global Blood Therapeutics to Neutral From Buy, Sets $68.50 Price Target	22-08-08	MT
Health Care Up Amid Deal Activity -- Health Care Roundup	22-08-08	DJ
Oppenheimer Downgrades Global Blood Therapeutics to Market Perform From Outperform	22-08-08	MT
Wedbush Downgrades Global Blood Therapeutics to Neutral From Outperform on Pfizer Acquisition, Lowers PT to $68.50 From $74	22-08-08	MT

Chart Global Blood Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Global Blood Therapeutics, Inc. is a biopharmaceutical company that discovers, develops and delivers treatments. The Company is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). It is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company's next-generation HbS polymerization inhibitor. The Company is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+3.13%	42.11B
LONZA GROUP AG	+48.83%	40.08B
MODERNA, INC.	+8.49%	40B
CELLTRION, INC.	-10.82%	26.87B
ICON PUBLIC LIMITED COMPANY	+8.26%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.69%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	11.94B
MEDPACE HOLDINGS, INC.	+32.83%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.63%	11.01B

Other Biotechnology & Medical Research